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Kobayashi and Noiri do not argue against the validity of
our reported significant correlations of TT and UFR with
mortality risk, but suggest that our report may offer an
underestimate of the true magnitude of potential benefits
from longer TT and slower UFR.
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To the Editor: Recently, Rule et al.1 demonstrated a 19%
higher glomerular filtration rate at the same cystatin C (Cys
C) level among patients after renal transplantation in
comparison to patients with native kidney disease. Thus, a
new Cys C-based formula (glomerular filtration rate-
76.6Cys C1.16) was suggested for transplant recipients
(TX formula). We analyzed the diagnostic performance of the
new TX formula in comparison to two other Cys C formulae
(Larsson and Hoek2,3) which are based on the same Cys C
assay in a cohort of 108 patients after renal transplantation.
Glomerular filtration rate was determined by 99mtechnetium-
labeled diethylenetriamine penta acetate clearance. Results
are given in Table 1.
Although the Larsson and Hoek formulae were not
derived from a transplanted cohort, their diagnostic perfor-
mances are at least comparable to the TX equation. Thus, two
conclusions can be drawn from this analysis: (1) calibration
differences between the different laboratories may counteract
the putative advantages of the new TX formula, (2) this
rather disappointing performance of the TX equation may
also be due to possible confounders like steroid dosing which
may crucially affect Cys C levels.4
To enhance the performance of future Cys C-based
glomerular filtration rate equations such cofactors should
be taken into account.
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We appreciate the work by Po¨ge et al.1 to test the
performance of our transplant equation.2 Remarkably,
the equation performed well with little bias (1.6 ml/min/
1.73 m2) in their transplant recipients. There was also little
bias with the Larsson3 and Hoek4 equations, which were
not specifically developed using transplant recipients.
However, we note that our finding of a higher glomerular
filtration rate (GFR) in transplant recipients (kidney or
other organ) compared to native chronic kidney disease
(CKD) patients is consistent with reports by other
investigators.5,6 In these centers, one equation cannot
accurately estimate GFR in both transplant and native
CKD patients unless it includes variables for transplant
Table 1 | Comparison of performance of the different cystatin C based formulae
Mean estimates
(ml/min/1.73 m2)
Range
(ml/min/1.73 m2)
Correlation
coefficient
Bias
(ml/min/1.73 m2)
Median
difference
(ml/min/1.73 m2)
Precision
(ml/min/
1.73 m2)
Accuracy within
30% (95% CI) 50% (95% CI)
DTPA 39.5 11.8–82.9
Larsson 36.3 7.78–104 0.859 3.20 4.78 9.59 77.1 95.4
Hoek 38.9 8.72–97.4 0.865 0.58 1.50 8.64 77.1 97.2
Rule 37.9 9.30–101 0.862 1.60 2.78 9.15 78.0 89.0
CI, confidence interval; DTPA, diethylenetriamine penta acetate.
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status or variables that better model the non-GFR factors
that affect cystatin C levels.
Equations are themselves a statistic of the average GFR
at each cystatin C level for a sampled population. As shown
in Figure 1, the bias between equations varies depending
on the cystatin C level. If one corrected for this bias
between equations, there would be no difference in the
statistics that reflect model error (R2, root mean square
error, precision, or accuracy within 30 or 50%). Additional
variables or further sub-population stratification would be
needed to decrease model error. It is possible that markers
of inflammation7 or glucocorticoid use8–10 would better
model the non-GFR variability with cystatin C than
transplant status. Given potential calibration differences
with cystatin C and ‘gold-standard’ GFR assays, it is a
stronger study design to refit equations with new
coefficients when comparing different populations,
different serum analytes, or different statistical models.
In addition, case mix and referral patterns for direct GFR
measurement likely differ among centers. To a different
extent between centers, patients referred for GFR measure-
ments may be influenced by discordance between the
clinical presentation and the serum creatinine.
The Larsson equation3 models unstandardized GFR (ml/
min) instead of standardized GFR (ml/min/1.73 m2);
however, body surface area is a predictor of unstandar-
dized GFR independent of cystatin C level.11 If we had
modeled unstandardized GFR with our data, inclusion of a
body surface area term in the model would have increased
our R2 from 0.700 to 0.777 in the transplant sample and
from 0.807 to 0.864 in the native CKD sample. The extent
that the average body surface area in the sample used to
derive the Larsson equation differs from 1.73 m2 will
contribute to bias between the Larsson equation and
equations that predict standardized GFR.
It is also worth noting that we used different data
transformations for deriving equations compared to the
Hoek equation.4 We regressed ln GFR on ln cystatin C,
instead of GFR on 1/cystatin C. If we had regressed GFR on
1/cystatin C with our data, the R2 would have been 0.719
instead of 0.768 in the transplant recipients sample and 0.806
instead of 0.853 in the native CKD sample. In addition, the
residual error with a 1/cystatin C model violated the
homoscedasticity assumption for linear regression. One
might expect a reciprocal relationship between cystatin C
and GFR based on clearance physiology: GFR¼ (cystatin C
production rate/serum cystatin C level)non-renal clearance
of cystatin C.12 However, our data and those by Larsson et al.3
found the relationship between GFR and cystatin C to be
stronger than a reciprocal relationship with an exponential
coefficient that was more negative than1. This suggests that
non-GFR factors (production rate or non-renal clearance
rate) are not independent of GFR with respect to their effects
on serum cystatin C levels, an assumption implicit with
1/cystatin C models.12 This lack of independence between the
non-GFR and GFR factors influencing a serum analyte is also
a limitation for serum creatinine equations.13,14
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Figure 1 | Comparison of the transplant (gray solid) and native
CKD (black solid) equations with the Hoek (black dashed) and
Larsson (gray dashed) equations. Equations are linear or nearly
linear on a logarithmic cystatin C (x axis) and logarithmic GFR (y axis)
scale.
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